Mon 7/15/2019 15:18 ET
DJIA27332.03245.990.90%TELCO175.850.460.26%GOLD1416.754.530.32%Shanghai2942.1911.770.40%
S&P 5003013.7713.860.46%BANKS448.375.921.32%OIL59.300.911.53%BITCOIN10889.99731.816.72%
NASDAQ8244.1448.640.59%PHARM566.943.170.56%US/EU1.130.000.00%Futures3016.380.900.03%
Welcome Stranger!  Please sign up or log in to enable additional features.Sign Up | Mail | Log In
Forum - Nabriva Therapeutics AG - NBRV   

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add NBRV
  
From: burp (Rep: 73)Date: 12/20/2018 07:14
Forum: Nabriva Therapeutics AG - Msg #93Thread #674053001 (Rec: 0)
$1.55 The two NDAs are supported by two pivotal, Phase 3 clinical trials (known as LEAP 1 and LEAP 2) that evaluated the safety and efficacy of IV and oral lefamulin compared to moxifloxacin in the treatment of adults with CABP, including the option to switch from IV to oral administration and a short course oral treatment with lefamulin. In both LEAP 1 and LEAP 2, lefamulin was demonstrated to be non-inferior to moxifloxacin, and met both the FDA and European Medicines Agency (EMA) primary and secondary efficacy endpoints for the treatment of CABP. Lefamulin was also shown to be generally well-tolerated when administered either orally or intravenously.

What would you like to do? Message: Endorse | Bookmark | Report AbuseUser burp: Reward | Watch | IgnoreNBRV: Ignore

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add NBRV
  

TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999- TheLion.com, Inc.